Lundbeck announces supportive phase II results with Lu AF82422 in the treatment of Multiple System Atrophy from the AMULET trial
· Signals of efficacy were observed across clinical and biomarker endpoints in a small exploratory proof-of-concept trial of 61 Multiple System Atrophy (MSA) patients (40 on Lu AF82422 versus 21 on placebo) · Although the AMULET trial did not show statistical significance on its primary endpoint in slowing the rate of progression of MSA as measured by UMSARS Total Score, a trend of a slowing MSA progression was observed in the group exposed to Lu AF82422 Valby, Denmark, January 31[st] 2024 - H. Lundbeck A/S (Lundbeck) announced results of the AMULET trial, a phase II, randomized,